---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-226747"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2026-05-15T20:13:11+00:00"
generated_at: "2026-05-15T20:19:47.775679+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics Q1 net loss $6.9M; REYOBIQ gets FDA Orphan Drug Designation

## Summary
- Cash and investments $15.1M as of March 31, 2026, up from $8.6M at Dec 2025 after $15M public offering.
- Net loss $6.9M ($1.05 per share) vs $17.4M in Q1 2025 (post reverse split).
- Revenue $1.0M from CPRIT grant and CNSide billings; operating loss $7.1M vs $3.5M year ago.
- FDA granted Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas and ependymoma.
- CNSide expanded payer coverage to ~81M lives including Blue Shield of California; unique PLA code secured.

## SEC filing metadata
- accession: 0001193125-26-226747
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2026-05-15T20:13:11+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000119312526226747/0001193125-26-226747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000119312526226747/pstv-20260515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-226747
- JSON: https://secwatch.observer/filing/0001193125-26-226747.json
- Plain text: https://secwatch.observer/filing/0001193125-26-226747.txt

## Key facts
- Earnings Releases
  PLUS THERAPEUTICS, INC. reported the first quarter ended March 31, 2026 results: revenue $1.0 million, net income $6.9 million, or $1.05 per basic share, EPS $1.05 per basic share. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2026
  - Revenue: $1.0 million
  - Net income: $6.9 million, or $1.05 per basic share
  - EPS: $1.05 per basic share
  - Guidance: reaffirmed
  - Result: reported results
  source text: 2026 public offering, partially offset by operating expenditures during the quarter and paydown of the investor liability at December 31, 2025 of $4.5 million • Recognized $1.0 million in revenue in the first quarter of 2026, including grant revenue from CPRIT for the advancement of REYOBIQ in LM and CNSide diagnostic billings, compared to $1.1 million in the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312526226747/0001193125-26-226747-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.